Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 13, 2007

VentiRx’ Deal with Array Enhances its Postion in TLR-based Therapeutics

  • VentiRx Pharmaceuticals obtained exclusive, worldwide rights to Array BioPharma’s Toll-like receptor (TLR) program. The program contains a number of development candidates targeting TLRs to activate innate immunity. VentiRx expects to develop its first two candidates in oncology and allergy.

    "These novel small molecule compounds from Array represent a significant opportunity for VentiRx and are ideally suited for our core competencies," says Michael Kamdar, executive vp and CBO at VentiRx. "This licensing agreement, coupled with our $28.9 million financing, puts us in a strong position to develop novel TLR-based therapeutics."

    Array will receive an equity stake in VentiRx, an upfront payment, potential milestones, and royalties on product sales. Array also retains the option to acquire a 50% ownership position in all VentiRx clinical oncology products developed.



Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »